Additional analyses show robust treatment effect of the therapeutic vaccine Diamyd®

Diamyd Medical has, as part of interactions with regulatory agencies, conducted two new analyses on the large meta-analysis dataset of 627 individuals that participated in four previous placebo controlled clinical trials evaluating the efficacy and safety of the therapeutic diabetes vaccine Diamyd[®]. Both analyses support the clinical relevance and significance of the treatment benefits of Diamyd[®], which further support the design of the Phase III trial DIAGNODE-3 which is planned to start recruiting patients later this year.“These two analyses show the robustness of our data and provide